Research programme: cannabinoid based therapeutics - Therapix Biosciences

Drug Profile

Research programme: cannabinoid based therapeutics - Therapix Biosciences

Alternative Names: Dronabinol/palmitoylethanolamide combination therapies - Therapix Biosciences; Palmitoylethanolamide; Palmitoylethanolamide combination therapies - Therapix; THX 120; THX 130; THX 150; THX-ULD01

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dekel Pharmaceuticals
  • Developer The Tel Aviv Sourasky Medical Center; Therapix Biosciences; Weizmann Institute of Science
  • Class Analgesics; Antibacterials; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Cognition disorders; Opioid abuse
  • Research Gilles de la Tourette's syndrome; Inflammation; Pain

Most Recent Events

  • 10 Nov 2017 Therapix Biosciences in-licenses synthetic cannabinoids for Opioid abuse from Yissum
  • 10 Nov 2017 Preclinical trials in Opioid abuse in Israel (unspecified route)
  • 09 Nov 2017 Early research in Cognition disorders in Israel (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top